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ORIGINAL ARTICLE
Tropism of engineered and evolved recombinant AAV
serotypes in the rd1 mouse and ex vivo primate retina
DG Hickey1, TL Edwards1, AR Barnard1, MS Singh1,2, SR de Silva1, ME McClements1, JG Flannery3, MW Hankins1,4 and RE MacLaren1,2,5
There is much debate on the adeno-associated virus (AAV) serotype that best targets specific retinal cell types and the route of
surgical delivery—intravitreal or subretinal. This study compared three of the most efficacious AAV vectors known to date in a
mouse model of retinal degeneration (rd1 mouse) and macaque and human retinal explants. Green fluorescent protein (GFP) driven
by a ubiquitous promoter was packaged into three AAV capsids: AAV2/8(Y733F), AAV2/2(quad Y-F) and AAV2/2(7m8). Overall,
AAV2/2(7m8) transduced the largest area of retina and resulted in the highest level of GFP expression, followed by AAV2/2(quad
Y-F) and AAV2/8(Y733F). AAV2/2(7m8) and AAV2/2(quad Y-F) both resulted in similar patterns of transduction whether they were
injected intravitreally or subretinally. AAV2/8(Y733F) transduced a significantly smaller area of retina when injected intravitreally
compared with subretinally. Retinal ganglion cells, horizontal cells and retinal pigment epithelium expressed relatively high levels of
GFP in the mouse retina, whereas amacrine cells expressed low levels of GFP and bipolar cells were infrequently transduced. Cone
cells were the most frequently transduced cell type in macaque retina explants, whereas Müller cells were the predominant
transduced cell type in human retinal explants. Of the AAV serotypes tested, AAV2/2(7m8) was the most effective at transducing a
range of cell types in degenerate mouse retina and macaque and human retinal explants.
Gene Therapy (2017) 24, 787–800; doi:10.1038/gt.2017.85
INTRODUCTION
Inherited retinal degenerations are a leading cause of blindness in
the working-age population of industrialised countries.1 Gene
therapy is a therapeutic approach that has great potential to slow
or reverse blinding retinal degeneration by delivering a normal
copy of a mutated gene2,3 (gene supplementation), editing the
mutated gene4 (for example, using CRISPR/Cas9), knocking down
the expression of a mutant allele using RNA interference5 or
expressing neuroprotective factors.6
Adeno-associated virus (AAV) is the vector of choice for most
retinal gene therapy applications where the transgene is relatively
small because of its established record of safety and efficacy in
preclinical studies and clinical trials.2,3,7,8 The efficacy of a vector is
measured by both the efficiency with which the genetic cargo is
delivered and its specificity for the target cell type (its tropism).
A greater understanding of AAV biology has led to the
generation of rationally designed recombinant AAV serotypes.
Mutation of surface tyrosine (Y) residues to phenylalanine (F) was
found to reduce the rate of proteasome-mediated degradation
and to significantly increase transgene expression in vitro and
in vivo, allowing a comparable transgene expression level to be
achieved with an ∼ 10-fold lower AAV dose.9 Subsequent work
showed further increased transduction efficiency and a wider
tropism by mutating two to seven surface tyrosine residues of
AAV2/2.(ref. 10)
AAV2/8, a serotype originally isolated from rhesus monkeys,11 is
effective at transducing photoreceptors and retinal pigment
epithelium more efficiently than AAV2/2 and AAV2/5 following
subretinal injection into nondegenerate mouse eyes.12
In additionally, AAV2/8 transduced photoreceptors of cynomolgus
monkeys more efficiently than AAV2/2 following subretinal
injection.13 Building on the findings from AAV2/2 site-directed
tyrosine to phenylalanine mutations, a capsid-mutant AAV2/8
serotype termed AAV2/8(Y733F) was developed that transduced
more cells and demonstrated significantly higher transgene
expression compared with wild-type AAV2/8.(ref. 14) Subretinal
injections of AAV2/8(Y733F) into nondegenerate mouse eyes led
to stronger and more widespread green fluorescent protein (GFP)
signal, compared with wild-type and mutant AAV2/2, AAV2/8 and
AAV2/9 variants.
In contrast to the targeted mutation approach, an in vivo
directed evolution strategy was used in mice to create novel AAV
serotypes that are more efficient at transducing murine photo-
receptors after being injected intravitreally.15 AAV2/2(7m8), an
evolved variant that features a 7-amino-acid sequence inserted
after position 587 of capsid protein VP1,15,16 was selected for
in vivo studies in mice and macaque and showed strong
expression across the retina and in all major classes of retinal
cells.15
The three serotypes selected for this study were: AAV2/8
(Y733F), AAV2/2(Y272, 444, 500, 730F) (abbreviated to ‘quad Y-F’)
and AAV2/2(7m8). Data directly comparing these leading AAV
vectors in degenerate retina are lacking. AAV2/8(Y733F) was
selected as a previous comparative study showed this to have the
greatest transgene expression intensity and transduction area
following subretinal delivery to nondegenerate mouse retina
compared with other AAV2/2, AAV2/8 and AAV2/9 serotypes.14
AAV2/8(Y733F) in conjunction with a ubiquitous promoter has also
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been demonstrated to transduce bipolar cells in the rd1 mouse.17
Of the AAV2/2 capsid mutants, AAV2/2(quad Y-F) was chosen for
further assessment as, when tested in nondegenerate mouse
retina, it has been found to transduce photoreceptors following
intravitreal injection, to occasionally transduce retinal bipolar cells
when delivered into the subretinal space and, overall, to
demonstrate a combination of high levels of transgene expression
and a diversity of transduced cell types that was not matched by
other AAV2/2 capsid mutants.10 Finally, AAV2/2(7m8) was selected
as it represents a contrasting approach to AAV development, has
demonstrated potent transduction across the retina in nonde-
generate mice and macaque retinas15 and has also been shown to
effectively transduce bipolar cells—a particularly challenging cell
target to transduce.18
This research aimed to test these three AAV serotypes in a
mouse model of retinal degeneration together with macaque and
human explants in vitro to inform AAV serotype selection for basic
and translational retinal research. As the end-stage degenerate
retina is the target tissue for a number of gene therapy strategies,
including optogenetic vision restoration,19 we compared the
transduction profile of the three recombinant AAV serotypes in a
model of retinal degeneration, the rd1 mouse, that has a naturally
occurring nonsense mutation of the rod-specific phosphodiester-
ase 6B (Pde6b) gene.20,21 In addition to the loss of photoreceptors,
the degenerate retina undergoes many structural, physiological
and gene expression changes that makes it distinct from the
nondegenerate retina22–25 and can cause changes in AAV spread
and transduction efficiency.26 This in vivo model enabled the
comparison of the area, intensity and cells types transduced by
the three AAV vectors following both intravitreal and subretinal
injections. Clinical data directly comparing intravitreal and
subretinal injections are lacking. We additionally tested the three
AAV serotypes in macaque and human explants to see whether
species-specific tropism differences that have been demonstrated
by in vivo studies27 were evident. The use of retinal tissue from
healthy macaque retina and degenerate human retina provided
some insight into disease-specific tropism differences. Comparison
with in vivo studies enabled an assessment of the utility of retinal
explants as models of in vivo transduction.
This study found that intravitreal and subretinal injections were
similarly effective for AAV2/2(quad Y-F) and AAV2/2(7m8), but the
subretinal route was more effective for AAV2/8(Y733F). All major
retinal cell types of the rd1 mouse retina were transduced, with
ganglion cells, horizontal cells and retinal pigment epithelium well
transduced, whereas bipolar cells were sparsely transduced. In
macaque and human retinal explants, AAV2/2(7m8) transduced
the greatest number of cells. These data support the use of
AAV2/2(7m8) in mouse models as well as primate retina.
RESULTS
AAV tropism in rd1 mice, a model of retinal degeneration
Intravitreal AAV2/2(7m8) transduces the greatest area of mouse
retina. Three recombinant AAV vectors were produced by
packaging the same expression cassette, consisting of GFP driven
by a ubiquitous CAG synthetic promoter with an SV40 poly(A)
sequence, into three different AAV capsids: AAV2/8(Y733F),
AAV2/2(quad Y-F) and AAV2/2(7m8). At 3 weeks after injection
with one of the three AAV-GFP test vectors, rd1 mice underwent
in vivo confocal scanning laser ophthalmoscopy to quantify the
distribution and intensity of GFP expression in the retina.
In all three intravitreally injected AAV vector groups the
area around the optic disc showed the most fluorescence
Figure 1. Scanning laser ophthalmoscopy of degenerate mouse retinas injected with three GFP-expressing AAV serotypes. (a–c) Mice were
injected at 13–14 weeks of age and assessed 3 weeks post injection by confocal scanning laser ophthalmoscopy (cSLO). Images centred on
the optic disc were acquired from each of the eyes injected with each of the following serotypes: (a) AAV2/8(Y733F), (b) AAV2/2(quad Y-F) and
(c) AAV2/2(7m8). The same autofluorescence settings were used. (d) SLO images were quantified by setting a threshold pixel value and
determining the area of each image above this threshold and (e) the intensity of the signal (‘Pixel value’) in the area above the threshold
(mean± s.e.m.; n= 4, AAV2/8(Y733F) and AAV2/2(quad Y-F); n= 3, AAV2/2(7m8)). *Po0.05, **Po0.01. Scale bar, 1 mm.
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(Figures 1a–c), in keeping with the high concentration of ganglion
cell axons in this region. In eyes injected with AAV2/2(quad Y-F) or
AAV2/2(7m8) the fluorescence extended beyond the central 55° to
the peripheral retina where it was strongest adjacent to blood
vessels. Fluorescence was mostly speckled, with small, highly
fluorescent foci.
GFP fluorescence did not appear to be limited to the boundary
of the bleb that was created to deliver AAV vector to the
subretinal space between the neuroretina and the retinal pigment
epithelium. In most eyes the subretinal bleb was limited to two
quadrants, but fluorescence was seen at all angles around the
optic disc (Figures 1a–c). Despite the AAV vector being delivered
Figure 2. Statistical analysis of immunohistochemistry data comparing delivery routes and AAV serotypes in degenerate rd1 mouse retinas.
(a) Ordinary two-way analysis of variance (ANOVA) tests examining the effect of delivery route (intravitreal or subretinal) and AAV serotype on
the area above threshold for each of the three layers of the retina were examined. Only the effect of delivery route and AAV serotype on the
area above threshold in the inner plexiform layer showed a statistically significant interaction between delivery route and area above
threshold, F(1, 11)= 5.2, P= 0.043 (n= 3, all groups except intravitreal AAV2/2(7 m8) (n= 2)). Simple effects analysis showed that the area above
threshold in the inner plexiform layer from a subretinal injection with AAV2/8(Y733F) was significantly lower than the area associated with an
intravitreal injection with AAV2/2(7m8). (b) Ordinary two-way ANOVA tests examining the effect of delivery route and AAV serotype on the
pixel value in each of the three layers of the retina showed no statistically significant interactions. *Po0.05.
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by a transchoroidal approach to the subretinal space in this group
of eyes, lines of fluorescence from the periphery to the optic disc
were notable in some eyes, consistent with GFP expression in
ganglion cell axons, indicating that AAV had traversed the retina
and transduced retinal ganglion cells in the innermost retinal layer
(Supplementary Figure 1).
GFP expression was quantified by assessing the area of GFP
expression above the background signal threshold and intensity
was compared using mean pixel values (Figures 1d and e).
Examining the effect of delivery route (intravitreal or subretinal)
and AAV serotype on transduced area showed a statistically
significant interaction between AAV serotype and area,
F(2, 17) = 5.1, P= 0.019 (Figure 1d; n= 4, all groups except
intravitreal AAV2/2(7m8) (n= 3)). Simple effects analysis with
Bonferroni correction showed that the area of GFP expression
from an intravitreal injection with AAV2/8(Y733F) (3.4 ± 1.9%) was
significantly lower than each of subretinal AAV2/8(Y733F)
(80.8 ± 10.2%; Po0.01), intravitreal AAV2/2(7m8) (91.1 ± 2.2%;
Po0.01) and subretinal AAV2/2(7m8) (75.0 ± 13.5%; Po0.05). An
ordinary two-way analysis of variance examining the effect of
delivery route and AAV serotype on pixel value showed no
statistically significant interactions (Figure 1e).
Hence, intravitreal injection with AAV2/8(Y733F) led to the
smallest area of transduced retina, but statistically significant
differences between other vector/delivery routes were not
detected.
Injection route determines relative transduction of retinal layers. To
compare the level of GFP expression across retinal layers, vertical
sections of the rd1 mouse eyes that had received injections of
three serotypes of AAV-GFP were prepared. To quantify penetra-
tion and transgene expression efficiency the retina was divided
into the three remaining layers (inner nuclear layer, inner
plexiform layer and ganglion cell layer) and the percentage area
above the background signal and the mean pixel value within the
area above threshold was calculated (Figure 2).
Of those eyes that received an intravitreal injection, AAV2/2
(7m8) produced the greatest area above threshold in all three
layers of the degenerate retina, with 10.1 ± 5.7, 29.8 ± 7.6 and
38.7 ± 4.1% of the inner nuclear layer, inner plexiform layer and
ganglion cell layer, respectively, above the threshold (Figure 2a).
The area transduced by AAV2/2(7m8) in the inner plexiform layer
and ganglion cell layer was notably higher than the transduced
areas from AAV2/8(Y733F) (3.9 ± 3.2 and 11.2 ± 5.7%, respectively)
and AAV2/2(quad Y-F) (12.0 ± 6.2 and 20.9 ± 8.4%, respectively)
intravitreal injections. In the inner nuclear layer, AAV2/2(quad Y-F)
and AAV2/2(7m8) groups had comparable areas transduced with
8.0 ± 4.1 and 10.1 ± 5.7%, respectively. The AAV2/8(Y733F) group
in contrast had 1.1 ± 1.1% of its inner nuclear layer above
threshold. Consistent with the confocal scanning laser
ophthalmoscopy results, an intravitreal injection with AAV2/8
(Y733F) was not as effective as the other two serotypes, with the
least area transduced in all layers of the degenerate retina.
A different pattern of GFP expression in the retinal layers was
evident following subretinal delivery of AAV vector. Generally,
subretinal injections resulted in more of the inner nuclear layer
and a smaller area of the ganglion cell and inner plexiform layers
being above threshold compared with retinas that had received
the same AAV by the intravitreal route (Figure 2a). A notable
exception to this pattern was with the use of AAV2/2(quad Y-F)
where the area of the ganglion cell layer above threshold was
higher following subretinal (25.1 ± 6.6%) versus intravitreal
(20.9 ± 8.4%) vector delivery (Figure 2a).
There was a statistically significant interaction between delivery
route and area above threshold in the inner plexiform layer,
F(1, 11) = 5.2, P= 0.043 (n= 3, all groups except intravitreal AAV2/2
(7m8) (n= 2); Figure 2a). Simple effects analysis showed that the
area in the inner plexiform layer from a subretinal injection with
AAV2/8(Y733F) (1.7 ± 1.5%) was significantly (Po0.05, Bonferroni
correction) lower than the area above threshold because of an
intravitreal injection with AAV2/2(7m8) (29.8 ± 7.6%). Ordinary
two-way analysis of variance tests examining the effect of delivery
route and AAV serotype on the pixel value in each of the three
layers of the retina showed no statistically significant interactions
(Figure 2b).
Horizontal cells, ganglion cells and retinal pigment epithelium are
strongly transduced by all three serotypes. To determine which
cell types of rd1 degenerate mouse retinas were transduced by
intravitreal or subretinal injection of three serotypes of AAV-GFP,
vertical sections were co-labelled with a range of antibody retinal
cell markers (Figure 3). The relative transduction efficiency of the
different serotypes did not differ greatly — the same cell types
were transduced in all cases (Table 1). The route of delivery also
did not influence which cell types were transduced; however,
there were differences in the level of expression of GFP in the
transduced cells depending on the delivery route.
The cell type most strongly transduced in the inner nuclear
layer following intravitreal or subretinal AAV vector delivery was
the horizontal cell, as identified by their position in the outer part
of the inner nuclear layer and positive staining with an anti-
calbindin antibody (Figure 3a). In retinas injected intravitreally or
subretinally, transduction of rod bipolar cells, identified by protein
kinase-Cα (PKCα) immunolabelling, was sparse (Figure 3b). When
transduced PKCα-positive cells were identified, their level of GFP
expression was very low compared with horizontal cells. A
population of amacrine cells were identified by immunolabelling
with antibodies against calbindin, glutamate decarboxylase 67
(GAD67) and glycine transporter 1 (GlyT1) (Figures 3a, c and d).
Retinas from each of the viral serotypes and delivery routes had
Figure 3. Confocal fluorescence micrographs of degenerate mouse retinas injected with three serotypes of AAV-GFP and double labelled for
GFP and retinal cell markers. Degenerate rd1 mouse retinas were injected either intravitreally or subretinally with an AAV vector expressing
GFP driven by a ubiquitous promoter, with one of three AAV serotypes: AAV2/8(Y733F), AAV2/2(quad Y-F) or AAV2/2(7m8). Vertical sections
were double immunolabelled for GFP and retinal cell markers: (a) calbindin; (b) protein kinase-Cα (PKCα); (c) glutamate decarboxylase 67
(GAD67); (d) glycine transporter 1 (GlyT1) or (e) brain-specific homeobox/POU domain protein 3a (Brn3a). Cell bodies that were
immunopositive for both GFP and the cell marker are encircled. Arrowheads indicate GFP-expressing retinal pigment epithelium (RPE). The
RPE cannot be identified in the majority of the panels because of it detaching during sample preparation. See Table 1 for a summary of the
colocalisation results. GCL, ganglion cell layer; INL, inner nuclear layer. Scale bar, 20 μm.
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amacrine cell marker-positive GFP-expressing cells in the inner
half of the inner nuclear layer. Generally, cells that were
immunolabelled with an amacrine cell marker were weakly GFP
positive as compared with the GFP levels expressed in horizontal
and ganglion cells.
Transduced cells in the ganglion cell layer included photo-
sensitive retinal ganglion cells, Brn3a-positive retinal ganglion cells
and amacrine cells. The majority of the GFP-positive cells in the
ganglion cell layer were Brn3a-positive retinal ganglion cells that
generally had a high level of GFP expression compared with other
cell types (Figure 3e). Brn3a-positive retinal ganglion cells were
observed irrespective of whether the AAV-GFP was injected
subretinally or intravitreally. A small number of GFP-positive cells
that co-labelled for calbindin or GAD67 were present in the
ganglion cell layer, suggesting that some displaced amacrine cells
were transduced (Figure 3c).
Sections from a retina that had received an intravitreal injection
of AAV2/2(7m8)-GFP were immunolabelled with an anti-mouse
melanopsin antibody, demonstrating that AAV2/2(7m8) trans-
duced melanopsin-positive photosensitive retinal ganglion cells
(Supplementary Figure 2).
All AAV-GFP vectors studied, regardless of serotype and delivery
route, showed high levels of GFP expression in retinal pigment
epithelial cells (data not shown).
AAV tropism in nondegenerate macaque retina
To compare the transduction pattern in mice to that of a primate,
the three serotypes of AAV-GFP were applied to explants of foveal
and peripheral retina from rhesus macaques (Macaca mullata)
ex vivo. At 8 days after adding 1010 vector genomes (vg) to each
explant, GFP expression was evident in immunolabelled explants.
GFP expression was strongest in the periphery of the foveal
explants, adjacent the cut edge (Figure 4). The AAV2/2(7m8)
transduced foveal explant featured higher levels of GFP expres-
sion that extended more centrally towards the foveola.
The pattern of cell types transduced was similar across the three
AAV serotypes, but AAV2/2(7m8) transduced explants had higher
levels of GFP expression spread over a larger area of retina
(Table 1). Vertical sections of foveal and peripheral retina explants
were immunolabelled for GFP and rhodopsin (anti-1D4 antibody).
Foveal explants were found to have significantly more widespread
and higher levels of GFP expression than peripheral retina
explants transduced with the same AAV serotype (Figure 5;
peripheral explant data not shown). The outer nuclear layer
contained the highest number of GFP-positive cells for all three
serotypes. Some explants had a cluster of GFP-positive cells in the
ganglion cell layer, but only towards an edge of the section
(Figure 5). Colocalisation studies showed that a large majority of
GFP-positive cells were cones—regardless of the serotype of the
AAV-GFP vector, calbindin colocalised with almost all of the GFP-
positive cells in the outer nuclear layer (Figure 6a). Only a small
number of GFP-positive, calbindin-negative cell rods were
identified in the inner part of the outer nuclear layer (Figure 6b).
GFP-positive cells in the ganglion cell layer were restricted to
the edge of the explants, where tissue damage was caused
when the explant disc was cut from the retina. Some of the GFP-
positive cells in the ganglion cell layer were noted to be
Brn3a positive (data not shown), whereas others were calbindin
positive (Figure 6b). In addition, at the periphery of a foveal
section, a GFP-positive cell in the inner nuclear layer was found to
co-label for PKCα (Figure 6c).
AAV tropism in human retinal explants
Explants of human retina fragments were also transduced with the
three different AAV-GFP serotypes. Human retina was acquired
from patients who required retinectomy during retinal detach-
ment surgery (Supplementary Figure 3). Hence, apart from species
differences, the human tissue was degenerate, providing addi-
tional information relevant to the clinical scenario. At 7 days after
immersing the explants in media containing 1.67 × 1010 vg per ml
of the AAV serotypes, the human retina samples were fixed and
immunolabelled for GFP and retinal cell markers.
Immunolabelling of transduced human retina samples showed
GFP expression across the width of each of the samples
transduced with an AAV-GFP vector (Figure 7). Whereas the
human retinal explant transduced with AAV2/8(Y733F) showed
GFP expression limited to cells largely in the inner nuclear layer
(Figure 7a), explants transduced with AAV2/2(quad Y-F) and
AAV2/2(7m8) showed extensive GFP expression in all layers of the
retina (Figures 7b and c). Rod bipolar cells were identified by
immunolabelling PKCα (Figure 8a). No GFP-positive cells were
found to be PKCα positive, suggesting very few rod bipolar cells
were transduced in these human retinal explants. Rod photo-
receptors were transduced, as shown by co-labelling with an anti-
1D4 antibody that binds to rhodopsin (Figure 8b). Transduced
cones were not identified (red/green opsin and cone arrestin
staining; data not shown), but this may be because of the low
number of cones in the peripheral retina where these samples
were taken from and/or compromised tissue health.
Figure 4. Macaque fovea explants transduced with three serotypes
of AAV-GFP. The 3 mm diameter discs of macaque retina centred on
the fovea were cultured for 8 days in AAV-GFP solution before being
fixed and immunolabelled with anti-GFP antibody. Three different
AAV serotypes were used to transduce different explants: AAV2/8
(Y733F), AAV2/2(quad Y-F) and AAV2/2(7m8). Images were acquired
using the same settings. The outer nuclear layer is nearest the
camera in all images. Scale bar, 500 μm.
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The extensive GFP expression in human retinal explants
transduced with AAV2/2(quad Y-F) and AAV2/2(7m8) had an
unusual pattern that was not stereotypical of a particular cell type
in a normal retina. However, some of the areas of GFP expression
that spanned the full thickness of the retina colocalised with glial
fibrillary acidic protein (and calbindin), suggesting some of these
cells were Müller cells (Figures 8c and d). A control human retinal
explant that was not transduced with an AAV-GFP vector did not
show any signal in the GFP channel (Figure 8e).
DISCUSSION
Engineered AAV serotypes have the potential to expand the
potency and cell targets of naturally occurring serotypes, thereby
facilitating the targeted delivery of gene therapies to previously
untreatable cell types and a reduction of therapeutic dose. This
study aimed to characterise three potent AAV serotypes as tools
for basic and translational research by comparing the cell types
transduced and the levels of transduction achieved by intravitreal
and subretinal injection of the degenerate mouse eye and
transduction of macaque and human retinal explants. Across the
three species tested, the AAV2/2(7m8) serotype was the most
efficient at transducing a wide area of a given retina and a diverse
range of cell types. In the degenerate mouse retina, AAV2/2(7m8)
injected either intravitreally or subretinally led to retinas having a
large area expressing GFP. AAV2/2(quad Y-F) also transduced
consistently across the three species, but not to the extent of
AAV2/2(7m8). AAV2/8(Y733F) transduction was more variable and
generally the lowest of the three.
The general pattern of GFP expression varied greatly between
mouse, macaque and human retinas. This may be because of
species-specific tropism factors as well as a combination of the
health status of the tissue and/or the experimental procedure. In
this regard, it is notable that the macaque tissue was isolated from
healthy fresh retina, whereas the human retinal samples were
obtained from patients undergoing retinectomy for long-standing
retinal detachments. As retinal injury is known to activate Müller
cells by expression of glial fibrillary acidic protein,28 this may also
influence viral tropism. The challenges of intraocular surgery—
including variability in the site of injection, the success of retinal
detachment and the speed of vector delivery—would have
contributed to the variability in the mouse in vivo results. This
variability mirrors the challenge of delivering AAV to patients.
In the degenerate mouse retina, horizontal cells, retinal gang-
lion cells and retinal pigment epithelium were the cell types that
had the greatest levels of GFP expression, regardless of the AAV
serotype injected (Table 1). Watanabe et al.29 performed subretinal
injections of AAV2/2 and AAV2/8 (no capsid mutations) into
nondegenerate retinas and also reported that horizontal and
ganglion cells were efficiently transduced, whereas amacrine cells
were less commonly transduced and bipolar cells were rarely
transduced. A previous study by our group demonstrated similar
patterns of retinal cell tropism following intravitreal and subretinal
injection of AAV2/8(Y733F).17
The predominant cell type transduced in the macaque retinal
explants was the cone photoreceptor (Table 1). GFP expression
was high in cones across the retina in samples that received
AAV2/2(7m8)-GFP, whereas GFP expression was greatest at the
outer edges of foveal explants that received AAV2/8(Y733F)-GFP
or AAV2/2(quad Y-F)-GFP. The lower density of cones in peripheral
retinal explants is thought to explain the overall lower level of GFP
expression in these samples. Previous studies have reported that
wild-type AAV2,30 AAV2/2(quad Y-F) and AAV2/2(7m8) intravitre-
ally injected into macaque eyes leads to a ring of fluorescence,
centred on the fovea15—suggesting a common mechanism
leading to poor transduction of the central fovea. The thickness
of the inner limiting membrane (ILM) may be a significant factor in
limiting foveal transduction in vivo and in explant cultures. The
ILM forms the interface between the retina and the vitreous and
consists of the plasma membrane of Müller cells, a dense basal
membrane and loose collagen fibrils extending into the vitreous
cortex.31 The ILM is much thicker (~400 nm) at the fovea
compared with the equatorial region of the retina and surround-
ing the optic disc, where it is ~ 70 nm thick,32 creating a greater
Figure 5. Fluorescence micrographs of foveal macaque retina explants transduced with three serotypes of AAV-GFP and double labelled for
GFP and rhodopsin. Macaque explants from the fovea were transduced with AAV-GFP with one of three serotypes—AAV2/8(Y733F), AAV2/2
(quad Y-F) or AAV2/2(7m8)—or no AAV. Explants were fixed, sectioned and double immunolabelled with antibodies against GFP and
rhodopsin (1D4) to show the distribution of GFP in the retinal layers. All sections are oriented with photoreceptors up. Note that these images
are from tissue that is unique from those samples shown in Figure 4. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
Scale bar, 200 μm.
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physical barrier to AAV penetration. The ILM role in limiting AAV
retinal transduction is supported by data demonstrating that
degrading the ILM using proteases33 or injection to the sub-ILM
space34 leads to enhanced retinal transduction.
GFP expression was also seen in the ganglion cell layer, but this
was often at the extreme periphery of the macaque explants. It
was unclear as to whether this peripheral transduction was
facilitated by the absence of the ILM as a barrier to diffusion, or
whether the trauma of creating the explant’s cut edge may have
enhanced transduction. It is possible that the periphery of each
explant effectively mimics the degenerate retina that has a more
permeable ILM26 or the thinner ILM of a rodent.33
The results of this study compare well with those reported by
Dalkara et al.15 In their study, AAV2/2(quad Y-F)-GFP (referred to as
AAV2-4YF-CMV-GFP by the authors) and AAV2/2(7m8)-GFP
(referred to as 7m8-CMV-GFP by the authors) were injected
intravitreally into one eye each of a Macaca fascicularis monkey. By
3 weeks after the injection, GFP expression was evident at the
fovea, with the AAV2/2(7m8)-GFP eye showing higher levels of
GFP expression. Although the current study used ex vivo explants
rather than in vivo injections into a different species (M. mullata),
and used a CAG promoter rather than the cytomegalovirus
promoter used by Dalkara et al.,15 it is interesting to note the
consistent finding of greater GFP transduction by AAV2/2(7m8)
compared with AAV2/2(quad Y-F).
Ramachandran et al.27 injected AAV2/2(7m8) (referred to as
AAV7m8 by the authors) by the intravitreal and subretinal routes
into the eyes of M. fascicularis. At the lowest dose (1 × 1010 vg)
they observed rods and few cones to be transduced, whereas at
higher doses (1 × 1011 and 1× 1012 vg) cones were efficiently
transduced. These high-dose results are similar to the ex vivo
retinal explant results of the current study, despite a lower dose
(only 1010 vg per explant) of AAV. This result may be explained by
the fact that AAV is contained in a fixed volume in an explant
culture, whereas in vivo AAV is effectively diluted by diffusion out
of the subretinal bleb and removal via the vasculature.
Furthermore, the retinal pigment epithelium removes AAV
particles in vivo.
The qualitative results obtained from transduction of human
retina samples shows that all three AAV serotypes transduced
human retinal cells relatively efficiently and that these serotypes
are likely to prove effective in targeting retinal neurons in vivo
(Table 1). Given that these retina samples typically came from
patients who had chronic retinal detachments, the transduced
Figure 6. Confocal fluorescence micrographs of macaque foveal explants transduced with AAV2/8(Y733F)-GFP, co-labelled for retinal cell
markers. (a) The majority of GFP-positive cells in macaque foveal explants were calbindin positive, indicating they were cones. (b) However, a
small number of GFP-positive photoreceptors were calbindin negative (arrowheads) that, combined with the slender inner segment
morphology of these cells and the more inner location of the cell bodies, suggests these are rods. Calbindin- and GFP-positive cells were also
identified in the ganglion cell layer (*). (c) At the very periphery of a flat-mounted explant, a PKCα-positive bipolar cell was co-labelled
(arrowhead). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar, 20 μm.
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areas of retina are likely to have abnormal physiology, and this
may explain the unusual patterns of GFP expression in some of
the samples. Activated Müller cells, for example, appeared to be
strongly transduced by AAV2/2(7m8) and AAV2/2(quad Y-F).
Müller cell activation is known to be a feature of proliferative
vitreoretinopathy seen in chronic retinal detachment.35 Consistent
with this explanation, such a pattern of GFP expression was not
identified in degenerate mouse or nondegenerate macaque
transduced retinal samples.
Consistent with previous studies, it was found that bipolar cells
had very low rates of transduction.36 Given that retinal bipolar
cells are an ideal target for optogenetic gene therapy,19 these low
rates of bipolar cell transduction are significant. It is likely that the
concentration of AAV required to effectively transduce retinal
bipolar and amacrine cells is relatively high. Effective bipolar cell
transduction using these AAV serotypes may therefore require
higher AAV concentrations than tested in this set of experiments.
Macé et al.18 achieved widespread bipolar cell transduction by
intravitreally injecting a high-concentration GFP-expressing AAV2-
/2(7m8) vector into rd1 mice. The number of vector particles
injected by Macé et al.18 was ∼ 60 × greater (1.8 × 1011 vector
particles injected/eye; vg concentration unknown) than the
number of viral genomes delivered in the current study
(3 × 109 vg/eye). This highlights the requirement for highly
concentrated AAV to achieve effective bipolar cell transduction.
The use of a bipolar cell-specific—rather than ubiquitous—
promoter may also be critical to increasing bipolar cell transduc-
tion efficiency, as has been demonstrated in mice.37
Transduction of primate bipolar cells has proved more
challenging than transducing mouse bipolar cells. Subretinal
injection of a high concentration (1 × 1012 vg) of AAV8BP2, a
capsid customised to bipolar cell transduction in mice, did not
efficiently transduce bipolar cells in nondegenerate retina of M.
fascicularis.27 In this study by Ramachandran et al.,27 minimal
bipolar cell transduction was achieved in M. fascicularis retina
following injection of high doses of AAV2/2(7m8) (1 × 1011 and
1× 1012 vg), the higher of which resulted in severe, chronic
inflammation.
The discrepancies between the cellular transduction patterns
between mice and macaques led Ramachandran et al.27 to
suggest that retinal explants from non-human primates or post-
mortem human samples may be more suitable for directed
evolution experiments to isolate serotypes suited for human
clinical applications. Given the similarity in appearance of the
current study’s explant sections and those from in vivo injections
reported by Ramachandran et al.,27 this study supports the use of
non-human primate explants as a model for directed evolution
of primate-optimised AAV serotypes. This approach has the
advantages of removing surgical variability and enabling
multiple variables to be tested in parallel using tissue from a
single animal.
A direct comparison of the intravitreal and subretinal routes of
delivery was completed as part of the studies in rd1 mice. AAV2/2
(7m8) and AAV2/2(quad Y-F) both transduced a similar area of the
retina regardless of their route of delivery. An important
consideration when deciding on a delivery route is the differences
in anatomy between the mouse and human eye. The human eye
has a vitreous cavity of much greater volume relative to the retinal
area, compared with that of a mouse eye. Therefore, the potential
for dilution throughout the vitreous cavity following an intravitreal
injection is much greater in the human eye. Intravitreal injections
additionally expose virions to cellular and extracellular off-target
receptors that may capture virions (effectively diluting the dose)
and/or initiate adverse effects by binding to elements involved in
immune responses. In contrast, a subretinal injection controls the
volume through which virions are distributed and limits the range
of receptors that the virions are exposed to. Other studies that
have injected the same AAV serotype intravitreally into mouse and
primate eyes have observed a much lower rate of transduction in
the primate eye.15
A limitation of this study was that all of the data were gathered
at a single time point—3 weeks after injection for the mouse
studies and ∼ 1 week for macaque and human explant studies.
Different serotypes can have different rates of expression because
of the different ways in which AAV capsids interact with cell
surface receptors and the rate at which the vector genome is
uncoated.38 AAV tropism outcomes have been assessed at 3 weeks
post injection in other studies,17 whereas others have assessed
outcomes in nondegenerate mice at 4 weeks.10 Natkunarajah
et al.12 found that in vivo fluorescence from AAV2/8 (no capsid
mutations) did not reach a plateau until 7 weeks post injection.
Longer-term data would be helpful to contrast with this data set
and to ensure that expression is sustained long enough to justify
clinical applications.
Figure 7. Fluorescence micrographs of human retina explants
transduced with three serotypes of AAV-GFP. Retina from patients
requiring retinectomy was cultured for 1 week in the presence of
AAV-GFP of three different serotypes: (a) AAV2/8(Y733F), (b) AAV2/2
(quad Y-F) or (c) AAV2/2(7m8). Explants were sectioned and
immunolabelled for GFP and cell markers, such as protein kinase-
Cα (PKCα, used in (a) and (b) only). GFP was largely limited to the
inner nuclear layer (INL) of AAV2/8(Y733F) transduced retina, but
extended throughout all retinal layers in retina transduced with
AAV2/2(quad Y-F) and AAV2/2 (7m8). GCL, ganglion cell layer; ONL,
outer nuclear layer. Scale bar, 20 μm.
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A further limitation of this study was that only one concentra-
tion of AAV vector was investigated. Studies have shown that the
number of vector genomes injected can have an important
influence on the transduction efficiency and pattern.14,39 The
number of vector genomes injected was limited by the lowest
concentration of the AAV preparations that were produced.
Variability in the size of human retinal explants also meant that
the multiplicity of infection could not be standardised. The use of
uniform sized discs of macaque retinas minimised multiplicity of
infection variability in macaque explants.
In summary, we report that an AAV variant developed by a
process of directed evolution, AAV2/2(7m8), effectively transduces
a range of cell types when delivered to the degenerate mouse
retina by intravitreal or subretinal injection as well as macaque
and human retinal explants. The rationally engineered serotypes
AAV2/8(Y733F) and AAV2/2(quad Y-F) also transduce multiple
retinal cell types across the three species, but to a lesser extent.
Differences in the pattern of transduction between mouse and
macaque suggest the thickness of the ILM may present a
significant barrier to effective retinal transduction following
intravitreal injection. These data demonstrate that AAV2/2(7m8)
should be considered a valuable vector for developing effective
clinical gene therapy strategies.
MATERIALS AND METHODS
Plasmids
A plasmid containing humanised GFP (GenBank accession number
U50963.1) driven by a ubiquitous CAG (CMV enhancer, chicken β-actin,
rabbit β-globin) promoter was a gift from Bill Hauswirth, University of
Florida (Gainesville, FL, USA).40
Plasmids containing the rep-cap genes to make AAV2/8(Y733F) and
AAV2/2(quad Y-F) AAV serotypes were created by site-directed mutagen-
esis, based on published mutation sites.9,41 The rep-cap plasmid to produce
AAV2/2(7m8) was a gift from John Flannery, University of California,
Berkeley.15 The 3.23 kb single-stranded sequence was packaged into three
different AAV capsids: AAV2/8(Y733F), AAV2/2(quad Y-F) and AAV2/2(7m8).
AAV production and titration
Recombinant AAV was produced using a triple transfection of 293T cells using
polyethylenimine followed by density separation by an iodixanol gradient and
buffer exchange using phosphate-buffered saline (PBS). Vector genome
concentration was determined by quantitative PCR comparison with plasmid
standards following DNase I (New England Biolabs, Ipswich, MA, USA) digest
and heat denaturation of AAV. For further details see Supplementary Methods.
Ethical review
Animal experiments were performed in accordance with the United
Kingdom’s Animals (Scientific Procedures) Act 1986. Experiments were
Figure 8. Fluorescence micrographs of human retina explants transduced with either AAV2/8(Y733F)-, AAV2/2(quad Y-F)- or AAV2/2(7m8)-GFP,
or no AAV and co-labelled for GFP and (a and e) protein kinase-Cα (PKCα), (b) rhodopsin, (c) glial fibrillary acidic protein (GFAP) or (d) calbindin.
(a, e) No cells were clearly double labelled for GFP and PKCα. (b) Explants transduced with both AAV2/2(quad Y-F)-GFP and AAV2/2(7m8)-GFP
were identified as co-labelled for GFP and rhodopsin, suggesting transduced rods (arrowheads). (c) AAV2/2(quad Y-F)-GFP and AAV2/2(7m8)-
GFP transduced retinas showed GFP colocalisation with GFAP (arrowheads). (d) Sections of AAV2/2(7m8)-GFP transduced retina were noted to
have cells that were both GFP and calbindin positive (arrowhead). (e) No GFP was identified in retina not exposed to either AAV. All sections
are oriented with the photoreceptors up. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar, 20 μm.
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performed at a Home Office-approved site (code: 30/2306) and under the
purview of a project licence (30/2808) that was approved and periodically
reviewed by the University of Oxford’s Clinical Medicine Animal Welfare
and Ethical Review Body and the Home Office.
The acquisition of human retina tissue from patients with retinal
detachment was approved by the Berkshire Research Ethics Committee,
part of the National Health Service’s National Research Ethics Service (REC
Code 10/H0505/8).
Animals
C3H/HeNCrl female mice (referred to as ‘rd1 mice’) were purchased from
Charles River (Wilmington, MA, USA). Mice were housed in individually
ventilated cages under a 12 h light (o100 lux)/dark cycle with the cage
temperature set to 21± 3 °C and 55± 10% relative humidity. Pellets of RM3
diet (Special Diets Services, Witham, UK) and water were available ad
libitum.
General anaesthesia
Mice were anaesthetised using 80 μg g− 1 of body mass of ketamine
(Vetalar, Zoetis, Florham Park, NJ, USA) and 10 μg g− 1 xylazine (Rompun,
Bayer AG, Leverkusen, Germany) administered via intraperitoneal injection
using a 1 ml insulin syringe and 29 G needle (Terumo, Tokyo, Japan).
Ketamine and xylazine were mixed together with the appropriate volume
of sterile water.
Anaesthestic reversal was achieved by intraperitoneal injection of
2 μg g− 1 of body mass of atipamezole (Antisedan, Orion Corporation,
Espoo, Finland), made up with sterile water.
Intraocular injections
Under general anaesthesia, each eye of female 13–14-week-old C3H/
HeNCrl mice was injected with ∼ 3 × 109 vg of one of three different
serotypes of AAV-GFP. One eye received an intravitreal injection, the other
a subretinal injection. Leakage of AAV from one eye to the contralateral
eye has not been demonstrated,42,43 and hence each eye was treat as
independent. Four eyes were injected for each combination of AAV
serotype and delivery route. In the absence of data quantifying the effect
size, the sample size was chosen based on the sample size of comparable
studies.14,17 Mice were selected randomly for injection with a given
serotype. To minimise the risk of contamination, mice were injected with
the same serotype. The surgeon was masked to the AAV serotype injected.
Further analysis was done in an unmasked manner.
After the induction of general anaesthesia, 1% (w/v) tropicamide and
2.5% (w/v) phenylephrine (Bausch & Lomb, Bridgewater, NJ, USA) were
applied to dilate the pupils. Carbomer gel (Viscotears; Alcon, Hünenberg,
Switzerland) was applied to both eyes and a 6∼mm diameter cover glass
(VWR International, Radnor, PA, USA) placed on the gel to enable
visualisation of the fundus.
AAV solution was thawed on ice and diluted to the appropriate
concentration with PBS, when necessary. Using a 5 μl syringe (65 RN,
Hamilton Company, Reno, NV, USA) and a 34 G, 10 mm long, point style 2
needle (Hamilton Company), 1–1.5 μl of AAV solution was aspirated with a
0.5 μl air bubble between the solution and the distal tip of the plunger. The
air bubble aided visualisation of the injection site.
An anterior chamber paracentesis was performed using a 1 ml insulin
syringe with a 29 G needle before subretinal injections to reduce ocular
pressure to aid globe manipulation and intraocular injection. Subretinal
vector delivery was performed under direct visualisation using an
operating microscope (Leica Microsystems, Wetzlar, Germany). The needle
was advanced through the sclera, choroid and retinal pigment epithelium
into the subretinal space. The injection site was posterior to the equator
and typically superotemporal in the left eye and superonasal in the right
eye. When the needle tip was visualised as being subretinal, the AAV
solution was injected. The appearance of air bubbles under the retina
confirmed a subretinal injection. Any mixed subretinal/intravitreal injec-
tions were excluded. The area of each retina exposed to a subretinal
injection was documented by manual drawings.
The procedure for an intravitreal injection did not include anterior
chamber paracentesis. The needle was passed through the sclera, choroid
and retina and into the vitreous cavity, where the solution was injected.
Seeing an air bubble against the posterior surface of the lens confirmed
the injection was intravitreal. The needle was left in situ for at least 30 s to
allow the intraocular pressure to normalise.T
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All injection wounds were allowed to self-seal. Following intraocular
injection, drops of 0.5% (w/v) chloramphenicol and 0.5% (w/v) proxyme-
tacaine hydrochloride (Bausch & Lomb) were applied to both eyes. Mice
were placed in a chamber warmed to ∼ 35 °C for the duration of their
recovery from anaesthesia. Mice were monitored for signs of ocular or
systemic health issues in the hours and days after an injection.
Between injections with the same AAV solution the needle and syringe
were flushed at least 10 times with sterile saline solution. Between
different AAV solutions the needles and syringe were flushed at least
20 times.
Confocal scanning laser ophthalmoscopy
Mice were imaged using a Spectralis HRA (Heidelberg Engineering,
Heidelberg, Germany) with general anaesthesia.
Pupillary dilation was achieved by the application of a 1:1 mixture of 1%
(w/v) tropicamide and 2.5% (w/v) phenylephrine (Bausch & Lomb) at least
5 min before imaging. A drop of hypromellose BPC 0.3% (w/v) (Martindale
Pharma, Romford, UK) followed by a custom-made contact lens was
applied to each cornea to prevent dehydration and cataract formation.44
In near-infrared mode (820 nm laser) with a 55° lens, the focal plane was
adjusted to the layer of maximum reflectance and an image acquired.
Changing to autofluorescence mode (488 nm excitation laser, 500–700 nm
emission detection), a series of images were acquired at sensitivity settings
40, 50, 60, 70, 80 and 90. The automated real-time feature, without
normalisation, was used to improve image quality. In near-infrared mode
the focal plane was moved to the inner retina to acquire images of the
ganglion cell layer in near-infrared and autofluorescence modes. Images of
other areas of interest were acquired, but not using standardised settings.
Quantification of scanning laser ophthalmoscopy images
Images were exported from Eye Explorer software (Heidelberg Engineer-
ing) as 1536 × 1536 pixel TIFF images. Images acquired at a sensitivity
setting of 70 were compared. Using ImageJ45 the images were converted
to 8-bit. A circular region of interest outlining the whole 55° field of view
was overlaid on each image. A minimum pixel value threshold was set to
30. This value was chosen as it included all areas that were subjectively
judged to be transduced. The minimum threshold value was kept constant
across all images. The measure function was used to calculate the
percentage of the area within the region of interest that was above the
threshold and the mean pixel value of the area above the threshold. These
data were copied into Excel (Microsoft, Redmond, WA, USA) for analysis.
One eye with media opacity was not included in the quantitative analysis.
Tissue collection
Mice were killed by cervical dislocation. Immediately following the
confirmation of death the eyes were enucleated. The cornea was
punctured using a 29 G needle (Terumo) and the eye immersed in 4%
formaldehyde in PBS at 4 °C overnight. After 16–24 h, the eye was rinsed in
PBS for ∼ 1 min before being immersed in 30% sucrose for at least the time
required for it to become negatively buoyant.
Embedding and sectioning of eyes and explants
Tissue that had been formaldehyde fixed and immersed in 30% sucrose
was briefly washed in PBS and transferred to a mould containing Optimum
Cutting Temperature (OCT; Tissue Tek, Sakura Finetek, Tokyo, Japan). After
5 min, the tissue was placed on pellets of dry ice. Once frozen the sample
was stored at − 80 °C.
Samples were sectioned using a cryostat (LM1850, Leica Biosystems,
Wetzlar, Germany). Cryostat temperature was typically between − 20 °C
and − 25 °C. Sections were 20 μm thick and were applied to Polysine slides
(Menzel-Gläser, Braunschweig, Germany).
Sections were left to dry at room temperature under metal foil for at
least 1 h before being stored at − 20 °C.
Immunohistochemistry: sections
Slides that had been stored at − 20 °C were dried at room temperature for
at least 1 h. Tissue was permeabilised with 0.2% Triton X-100 (Sigma-
Aldrich, St Louis, MO, USA) in PBS for at least 20 min at room temperature.
Sections were rinsed with PBS for at least 1 min before blocking with 10%
donkey serum in 0.2% Triton X-100 in PBS for at least 1 h at room
temperature. Primary antibodies were diluted (Table 2) in 2.5% donkey
serum and 0.2% Triton X-100 in PBS. Slides were placed in a humidified
box and placed at 4 °C overnight. When double or triple labelling the two
or three, respectively, primary antibodies were mixed together and applied
in a single solution.
Sections were washed by covering in 0.05% Tween-20 in PBS for at least
10 min. This was repeated four times. Secondary antibodies were diluted
1:200 in 2.5% donkey serum and 0.2% Triton X-100 in PBS. Slides covered
with secondary antibody solution were placed in a humidified dark box
and incubated at room temperature for 2 h.
Sections again underwent four washes with 0.05% Tween-20 in PBS for
at least 10 min for each wash. One final wash was completed with water.
Slides were mounted with ProLong Gold with DAPI mountant (Invitrogen,
Waltham, MA, USA) and placed in a dark box at room temperature
overnight. After the mountant had set, the slides were stored at 4 °C.
Immunohistochemistry: flat mounts
Visualised through a dissecting microscope the retina was removed from
the eyecup and transferred to 30% sucrose in a microcentrifuge tube.
To facilitate antibody penetration, the retina was freeze-fractured using
liquid nitrogen. The sample was placed in liquid nitrogen and left to freeze.
The tube was removed and thawed at room temperature. Degenerate
retinas underwent one freeze–thaw cycle, whereas nondegenerate retinas
had two cycles.
Retinas were permeabilised by immersion in 1% Triton X-100 for 10 min,
repeated three times. Retinas were blocked by immersion in 10% donkey
serum for at least 2 h (typically overnight). Primary antibodies were diluted
in 2.5% donkey serum and 1% Triton X-100 in PBS. Retinas were incubated
in primary antibody solution for up to 3 days at 4 °C.
Retinas were washed with 0.2% Triton X-100 in PBS three times, with
each step lasting at least 30 min on an orbital shaker. Secondary antibodies
were diluted 1 in 200 with 2.5% donkey serum and 1% Triton X-100 in PBS
and incubated in the dark overnight at 4 °C.
Retinas were washed with 0.2% Triton X-100 in PBS four times, each step
lasting at least 40 min on an orbital shaker. During the fourth wash step
Hoechst 33342, diluted 1 in 5000 in PBS, was added. A final wash was done
with water. Visualised under a dissecting microscope the retina was
cleaned of debris and cuts were made to enable it to be flattened. The
retina was transferred to a Polysine slide, with the ganglion cell layer facing
up. The retina was dried before applying ProLong Gold mountant. A
coverslip was lowered onto the retina and bubbles displaced. The slide was
left in the dark at room temperature overnight for the mountant to set
before being stored in the dark at 4 °C.
Image acquisition
Micrograph images were acquired using an inverted epifluorescence (Leica
Microsystems) or an inverted confocal (Carl Zeiss, Oberkochen, Germany)
microscope. Settings were optimised to minimise signal interference and
avoid image saturation. Where quantitative or semiquantitative compar-
isons between samples were to be made, the acquisition settings were
kept constant.
Using ImageJ, minimum and maximum pixel values of the whole image
were adjusted to aid visualisation of relevant features in figures.
Confocal imaging
Slides that had undergone the slide immunohistochemistry protocol in
parallel were imaged on an inverted confocal microscope under
standardised conditions. Using a 40 × oil immersion lens, two sections
from each slide were imaged. Two slides per eye were imaged, providing
representative coverage across the eye. Images were acquired from areas
of high fluorescence that were not at the extreme periphery of the retina,
adjacent to optic nerve or at an obvious injection site. Within the section
the imaging plane was set to that what gave the greatest total
fluorescence, as judged subjectively. The pinhole was set to 1 Airy unit
for the green channel. For image snaps that were to be compared, laser
power, gain, speed, averaging and image resolution were kept constant
after being set to minimise pixel saturation.
Using ImageJ, each image was manually segmented into the inner
nuclear layer, inner plexiform layer and ganglion cell layer using the
polygon selection tool. A threshold minimum pixel value was set and the
measure tool used to calculate the percentage area and mean pixel value
of each of the three regions of interest of each image, as previously
described.17 This objective technique is less susceptible to subjective cell
counting errors and has comparable outcomes.46 These data were copied
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into Excel. The mean of the percentage area and pixel value from the
multiple images of a given eye (technical replicates) was used as the value
to compare between eyes of different animals (biological replicates).
Macaque retinal explants
Rhesus macaque (M. mullata) eyes were obtained from the MRC Centre for
Macaques (Porton Down, UK). Tissue was collected post mortem from male
and female macaques ranging in age from 5 to 19 years (mean: 14.8 years
old) undergoing planned killing for other purposes. After sedation with
10 mg kg− 1 intramuscular ketamine and a lethal overdose of 200–
300 mg kg− 1 intravenous pentobarbitone, the eyes were immediately
enucleated. In a dish of complete neurobasal A (see below) the cornea and
lens were removed and radial incisions made to flatten the retina. A 3 mm
diameter biopsy tool was used to take discs of neuroretina from the fovea
and from around the vascular arcades (referred to as peripheral samples).
Retinal pigment epithelium separated from the neuroretina and hence was
not transferred. Using a transfer pipette (Sarstedt, Nümbrecht, Germany)
each retinal disc explant was transferred to a tube containing chilled
complete neurobasal A that was stored in a cooled polystyrene box for
transport to the laboratory (a period of 2–6 h).
In the laboratory, each retinal disc was placed in a tissue culture insert
(0.4 μm pore size, VWR International) in a well of a 24-well plate. Then,
500 μl of complete neurobasal A was placed in each well below the insert
and 200 μl in the insert. Explants were cultured at 34 °C, 5% CO2.
Complete neurobasal A was made of penicillin (final concentration: 100
units per ml), streptomycin (100 μg ml− 1; Sigma-Aldrich), L-glutamine
(800 μM; Sigma-Aldrich), B-27 supplement (2%; Gibco, Waltham, MA, USA)
and N-2 supplement (1%; Gibco) in neurobasal A (Gibco).
Two biological replicates were used for each AAV serotype and for both
foveal and peripheral samples.
Human retinal explants
Human retina samples were obtained from consented patients in an ethics
approved clinical study, in which retinal tissue was being removed as part
of their standard care. The surgery involved a limited retinectomy for
retinal detachment at the Oxford Eye Hospital. Patients were aged 39, 60
and 83 years. Depending on the surgical requirements the retinectomy
was performed by the vitreoretinal surgeons with ophthalmic surgical
scissors or with a 20 G or 23 G vitrector. Samples were removed from the
eye using a backflush flute needle and ejected into a sterile sample bottle
containing balanced salt solution.
Within 1 h, samples were placed into a tissue culture insert (0.4 μm pore
size) placed in a well of a 24-well plate. Then, 400 μl of complete
neurobasal A was placed in each well below the insert and 300 μl placed in
the insert. Explants were cultured at 34 °C, 5% CO2.
Two biological replicates were used for each AAV serotype. Technical
replicates were not possible because of the limited amount of tissue
available.
AAV transduction of primate retinal explants
Approximately 24 h after retina explant cultures began, the media were
replaced with complete neurobasal A and a volume of AAV containing
1010 vg to a total volume of 600 μl (final concentration 1.67 × 1010 vg per
ml). Explants were incubated at 34 °C, 5% CO2. Media were replaced every
2 days. The porosity of the membrane on which the explants rested meant
that it was assumed that explants were surrounded by AAV on all surfaces.
Investigators were not masked to which AAV serotype was applied.
Fixation of retinal explants
At 7 days after AAV was applied, explants were fixed. Explants were
washed in PBS and fixed in 4% formaldehyde (Thermo Fisher Scientific,
Waltham, MA, USA) in PBS for 2 h at room temperature. Following another
wash in PBS, explants were placed in 30% sucrose (w/v in PBS; Sigma-
Aldrich) and stored at 4 °C.
Statistical analysis and graphing
Statistical analysis and chart preparation was completed using Prism
(GraphPad, San Diego, CA, USA).
When comparing two independent variables, with at least two
conditions and a single dependent variable, an ordinary two-way ANOVA
was used. The post hoc tests were conducted with Bonferroni’s multiple
comparisons tests. When available, sample groups were all compared with
a single control group. When not available, all groups were compared with
each other. The significance level was α=0.05 for all tests.
Graphical data are presented as mean± s.e.m.
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